These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Hematopoietic growth factors in the treatment of acute myeloblastic leukemia]. de la Rubia Comos J Sangre (Barc); 1997 Apr; 42 Suppl 1():32-3. PubMed ID: 9381298 [No Abstract] [Full Text] [Related]
45. [Report on the current indications for colony stimulating factors (G-CSF and GM-CSF)]. Med Clin (Barc); 1994 May; 102(19):747-50. PubMed ID: 7518884 [No Abstract] [Full Text] [Related]
46. [Hematopoietic tissue growth factors: clinical factors]. Polli EE; Foa P Ann Ital Med Int; 1991; 6(1 Pt 1):69-81. PubMed ID: 1716450 [TBL] [Abstract][Full Text] [Related]
47. [G-CSF versus GM-CSF in the treatment of neutropenia in a patient with Felty's syndrome on hemodialysis]. del Pozo C; Ortiz de Salazar MI; Torregrosa I; Sánchez L; Albero MD; Bauza J Nefrologia; 2000; 20(5):455-8. PubMed ID: 11100668 [TBL] [Abstract][Full Text] [Related]
48. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children]. Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890 [TBL] [Abstract][Full Text] [Related]
49. A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. Croockewit AJ; Bronchud MH; Aapro MS; Bargetzi MJ; Crown J; Gratwohl A; Lange W; Ludwig H; Martinelli G; Mertelsmann R; Nuessler V; Willemze R; De Witte TJ; Zittoun R; Zwierzina H Eur J Cancer; 1997 Oct; 33(11):1732-46. PubMed ID: 9470826 [No Abstract] [Full Text] [Related]
50. [The dilemma of stimulating factors in the recovery from chemotherapeutic neutropenia]. Borbollo Escoboza JR; González Avante M; Alvarado Ibarra M Rev Invest Clin; 1996; 48(4):328. PubMed ID: 8966397 [No Abstract] [Full Text] [Related]
51. The benefits of haematopoietic growth factors in the management of gynaecological oncology. Dale DC Eur J Gynaecol Oncol; 2004; 25(2):133-44. PubMed ID: 15032269 [TBL] [Abstract][Full Text] [Related]
52. Colony-stimulating factor use in the context of refined risk and benefit assessments. Crawford J Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):9-10. PubMed ID: 16736982 [No Abstract] [Full Text] [Related]
53. Hematopoietic growth factors for chemotherapy-induced neutropenia. Yalçin S Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202 [No Abstract] [Full Text] [Related]
56. Clinical applications of hematopoietic growth factors in pediatric oncology. Levine JE; Boxer LA Curr Opin Hematol; 2002 May; 9(3):222-7. PubMed ID: 11953668 [TBL] [Abstract][Full Text] [Related]
57. Indications and guidelines for the use of hematopoietic growth factors. Goodnough LT; Anderson KC; Kurtz S; Lane TA; Pisciotto PT; Sayers MH; Silberstein LE Transfusion; 1993; 33(11):944-59. PubMed ID: 7505068 [No Abstract] [Full Text] [Related]
58. Hematopoietic growth factors for the treatment of aplastic anemia. Kumar M; Alter BP Curr Opin Hematol; 1998 May; 5(3):226-34. PubMed ID: 9664165 [TBL] [Abstract][Full Text] [Related]